BioMarin Pharmaceutical | BMRN - Gross Profit On Sales


BioMarin Pharmaceutical reported $571.21M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Bayer EUR 6.94B 1.58B Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Insmed USD 256.46M 38.78M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 3.02B Dec/2025
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026